{"id":4205,"date":"2025-03-31T18:12:01","date_gmt":"2025-03-31T18:12:01","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/mivacurium-txt\/"},"modified":"2025-03-31T18:12:01","modified_gmt":"2025-03-31T18:12:01","slug":"mivacurium-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/mivacurium-txt\/","title":{"rendered":"Mivacurium.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nNon-depolarising muscle relaxant of short duration

DOSE IN NORMAL RENAL FUNCTION <\/H3>IV injection: 70\u2013250 micrograms\/kg; maintenance 100 micrograms\/kg every 15 minutes

IV infusion <\/H4>: maintenance of block 8\u201310 micrograms\/kg\/minute, adjusted to maintenance dose of 6\u20137 micrograms\/kg\/minute according to response

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :1029; (1100.2 as chloride)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.1\u20130.3<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u201310 minutes\/ \u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Adjust to response. Slower infusion rate may be required
  • 10 to 20 &nbsp &nbsp : Adjust to response. Slower infusion rate may be required
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Reduce dose.

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Adjust infusion to response<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Adjust infusion to response
  • HDF\/high flux &nbsp :Unknown dialysability. Adjust infusion to response
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Adjust infusion to response

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced muscle relaxant effect\n
  • Anti-arrhythmics: procainamide enhances muscle relaxant effect\n
  • Antibacterials: effect enhanced by aminoglycosides, clindamycin, polymyxins and piperacillinBotulinum toxin: neuromuscular blockade enhanced, (risk of toxicity)

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>_

    Route <\/H4>IV bolus,

    IV infusion <\/H4>

    Rate of Administration <\/H4>IV bolus: Doses of up to 0.15 mg\/kg may be administered over 5\u201315 seconds. Higher doses should be administered over 30 seconds

    Comments<\/H4>Compatible with sodium chloride 0.9%; glucose 5%; dilute to 500 micrograms\/mLCompatible with fentanyl, alfentanil, droperidol and midazolam

    OTHER INFORMATION <\/H4>Spontaneous recovery is complete in approximately 15 minutes and is independent of dose administeredIn patients with CKD 5 the clinically effective duration of block produced by 0.15 mg\/kg is approximately 1.5 times longer than in patients with normal renal function; hence, dosage should be adjusted according to individual clinical responseResults from a study comparing 20 anephric patients with 20 healthy patients highlight the need for reduced dosages of Mivacron in patients with renal failure: patients with renal failure had a slightly shorter time to maximum depression of T1\/T0, a slower recovery of T1\/T0 to 5% (15.3 vs 9.8 min), required a slower infusion rate (6.3 vs 10.4 micrograms\/kg\/min) and experienced slower spontaneous recovery (12.2 vs 7.7 min). The drug company has no specific guidelines as to the extent of dose reduction required.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Non-depolarising muscle relaxant of short duration DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4205","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4205"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4205\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}